In the first half of this year, the top ten R & D investment of pharmaceutical listed companies was announced!

[pharmaceutical network industry trends] pharmaceutical industry is a high-tech enterprise Its R & D and innovation ability directly determines the survival and development of the enterprise, and also represents the core competitiveness of the enterprise In recent years, more and more domestic pharmaceutical enterprises have realized the importance of innovation for enterprises, and began to adjust the strategic deployment in time following the changes of policies and industry environment, continuously increase R & D investment and continuously introduce high-level R & D talents Now, how about the R & D investment of domestic pharmaceutical enterprises? A few days ago, an institution released a list of 232 pharmaceutical listed companies' R & D investment in the first half of 2019, with a total of 17.144 billion yuan invested in R & D, of which the R & D of Beida pharmaceutical accounted for a high proportion, up to 94.86% According to the list, the author combed the specific situation of the top ten listed pharmaceutical companies with R & D investment, hoping to provide reference for you In 2019, the R & D investment of 232 pharmaceutical listed companies ranked first in the top 10 The R & D investment of Beida Pharmaceutical Co., Ltd was 323100000 yuan, and the R & D investment accounted for 94.86% On August 26, Beida Pharmaceutical Co., Ltd issued a semi annual report, which showed that the company's semi annual operating revenue was 761988254.58 yuan, an increase of 31.08% year-on-year, and the net profit attributable to the shareholders of the listed company was 87336 yuan, 093.49 yuan, a year-on-year increase of 30.99%, with a total operating cost of 340622100 yuan The proportion of R & D expenditure reached 94.86%, which may be related to the substantial increase of early projects of the company II R & D investment of micro core biology: 22.0416 million yuan, R & D proportion: 56.50% Last month, micro core biology released the 2019 half year report From January to June 2019, the company realized an operating revenue of 81.9175 million yuan, a year-on-year increase of 12.77% The chemical pharmaceutical industry has disclosed an average operating revenue growth rate of 11.88% for the half year reports; the net profit attributable to shareholders of listed companies is 17.5101 million yuan, a year-on-year decrease of 2.33% The chemical pharmaceutical industry has disclosed an average net profit for the half year reports The growth rate is 3.81%; the total operating cost is 39.0138 million yuan Micro core bio is expected to operate well from January to September 2019, with earnings in the first three quarters III R & D investment of Puli pharmaceutical: 72.4021 million yuan, R & D ratio: 50.81% On August 22, Puli pharmaceutical released the semi annual report During the reporting period, the company realized an operating revenue of 351870600 yuan, an increase of 40.34% over the same period of last year; a total profit of 126762700 yuan, an increase of 61% over the same period of last year; a net profit of 120.0845 million yuan, an increase of 70.81% over the same period of last year, attributable to shareholders of listed companies; and an investment of 142.5047 million yuan in research and development IV R & D investment of Mingde Bio: 16.4701 million yuan, R & D ratio: 48.59% On August 22, Mingde bio issued the semi annual report According to the announcement, the company's semi annual operating revenue was 101860049.62 yuan, an increase of 4.05% year-on-year The net profit attributable to shareholders of the listed company was 40260045.02 yuan, an increase of 3.95% year-on-year The total operating cost was 33.8951 million yuan, and the net profit was 32.4217 million yuan, a decrease of 14.24% year-on-year, Mingde Bio said that in the first half of the year, the main reason for the decrease in net profit was the substantial increase in the company's R & D expenses and management expenses during the reporting period, among which the increase in R & D expenses was due to the company's increased investment in independent R & D projects, the significant increase in management expenses was due to the company's increased investment in operation management, the company's management structure was reorganized and the company's operation was improved Management efficiency Five, R & D investment of Wuhan Biological Engineering Co., Ltd.: 2742.23 (10000 yuan), R & D proportion: 44.03%, issued the semi annual report on August 14th According to the announcement, the company's semi annual operating revenue was 274337272.82 yuan, an increase of 25.43% year on year, the net profit attributable to shareholders of the listed company was 130478340.23 yuan, an increase of 25.53% year on year, and the total operating cost was 62.2823 million yuan In the first half of 2019, in accordance with the annual business plan, Wuhan Biological Technology Co., Ltd continued to improve the comprehensive R & D capacity of drugs, and constantly improved the coverage capacity of the company's products in the field of allergic diseases Some R & D projects made phased progress, and the company gradually formed a pattern of collaborative development of multiple products in the field of allergic diseases diagnosis and treatment Vi R & D investment of Kanghong Pharmaceutical Co., Ltd.: 283991600 yuan, R & D ratio: 42.41% Kanghong Pharmaceutical Co., Ltd issued a report for the half year of 2019, realizing operating revenue of 1.519 billion yuan (+ 9.79%) in the first half of the year; net profit of 340 million yuan (+ 9.67%), non net profit of 316 million yuan (+ 18.07%), total operating cost of 669.6794 million yuan, and steady growth of the company's revenue end and profit end In the first half of the year, the net cash flow from operating activities was 239 million yuan (+ 71.14%), with good operating quality and a substantial increase in cash flow, mainly due to the increase in the amount of sales of goods received At present, Kanghong pharmaceutical has successfully completed the first half of the year with Israel ioptima Ltd The third stage of equity delivery, 80% equity The ophthalmic product line is expected to expand, cut into the field of ophthalmic devices and consumables, further promote the pace of international strategy, and expand the global market 7 R & D investment of shutaishen: 70.5278 million yuan, accounting for 41.51% of the total On August 27, the 2019 China Daily published by shutaishen showed that its operating revenue was 345 million yuan, down 22.43% year on year; net profit attributable to shareholders of listed companies was 35.7 million yuan, down 63.12% year on year; total operating cost was 169.982 million yuan Since 2019, shutaishen's research projects have been accelerated, R & D personnel have increased, and R & D costs have continued to grow The sales volume of the company's products shutaiqing has achieved rapid and steady growth, and the sales revenue has increased significantly VIII Investment in research and development of idebio: 40.5394 million yuan, accounting for 39.81% of the total In the first half of 2019, idebio achieved an operating revenue of 270 million yuan, a year-on-year increase of 31.3%; a net profit of 78.16 million yuan, a year-on-year increase of 12.34%; including a total operating cost of 101.8322 million yuan During the reporting period, the company's overall revenue growth was steady, including the revenue from testing reagents of 2.2 yuan, a year-on-year increase of 17.7%, and the revenue from testing services of 47.25 million yuan, a year-on-year increase of 180.5%, showing outstanding performance IX R & D investment of Hengrui pharmaceutical: 1484.1152 yuan, R & D ratio: 39.35% Hengrui pharmaceutical released the 2019 half year report During the reporting period, the operating revenue of Hengrui pharmaceutical reached 10.026 billion yuan, an increase of 29.19% over the same period of last year; the net profit attributable to shareholders of listed companies was 2.412 billion yuan, an increase of 26.32% over the same period of last year; the total operating cost was 377195.24 The announcement also said that in the first half of 2019, Hengrui pharmaceutical's performance grew steadily, mainly driven by two factors: first, the harvest of innovation achievements, driving revenue generation from the source; second, the optimization of product structure, so as to achieve diversified and coordinated layout X R & D investment of xinlitai: 70.5278 million yuan, R & D ratio: 39.13% In the first half of 2019, the actual operating revenue of the company reached 2.356 billion yuan, an increase of 3.92%; non net profit growth of - 23.68%, sales expense growth of 31.96%, R & D expenditure growth of 27.44%, and total operating cost of 82913.21 This means that based on the 60% price reduction of clopidogrel in one third of the mainland, the actual performance of the company should be increased The company's net profit has been eroded due to the significant increase in sales expenses (a year-on-year increase of 190 million yuan) caused by the promotion of new products (tegralol, pivastatin, coronary stent) and the continuous investment in R & D expenses (a year-on-year increase of 70 million yuan).